Detalhe da pesquisa
1.
Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab).
Breast Cancer Res Treat
; 164(3): 571-580, 2017 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-28484925
2.
Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.
Cancer
; 119(15): 2675-82, 2013 Aug 01.
Artigo
Inglês
| MEDLINE | ID: mdl-23744760
3.
Utility of monocyte HLA-DR and rationale for therapeutic GM-CSF in sepsis immunoparalysis.
Front Immunol
; 14: 1130214, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-36825018
4.
HER-2/neu diagnostics in breast cancer.
Breast Cancer Res
; 9(3): 207, 2007.
Artigo
Inglês
| MEDLINE | ID: mdl-17561991
5.
Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer.
Clin Breast Cancer
; 5(2): 105-16, 2004 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-15245613
6.
Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients?
Biomark Cancer
; 5: 31-9, 2013 Aug 12.
Artigo
Inglês
| MEDLINE | ID: mdl-24179396
7.
Microfluidics and circulating tumor cells.
J Mol Diagn
; 15(2): 149-57, 2013 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-23266318
8.
Hidden HER-2/neu-positive breast cancer: how to maximize detection.
IDrugs
; 12(4): 238-42, 2009 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-19350468
9.
Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.
Cancer
; 113(6): 1294-301, 2008 Sep 15.
Artigo
Inglês
| MEDLINE | ID: mdl-18661530
10.
Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers.
Expert Rev Mol Diagn
; 7(3): 309-19, 2007 May.
Artigo
Inglês
| MEDLINE | ID: mdl-17489737
11.
HER2 status is an important biomarker in guiding personalized HER2 therapy.
Per Med
; 2(4): 317-324, 2005 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-29788570
12.
Value of serum human epidermal growth factor receptor 2 (HER2)/neu testing for early prediction of response to HER2/neu-directed therapies is still an open one and deserves further study in large prospective trials.
J Clin Oncol
; 27(36): e273; author reply e274-5, 2009 Dec 20.
Artigo
Inglês
| MEDLINE | ID: mdl-19917836
13.
Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer.
Clin Chem
; 49(10): 1579-98, 2003 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-14500583